NASDAQ: ARVN · Life Sciences · 2 alerts · CIK 1655759
Share price
$6.77Close, Nov 16
Market cap
$443M
Shares outstanding
65.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Arvinas, Inc. filings on SEC EDGAR ↗
Arvinas, Inc. reported total assets of $607.5 million as of September 30, 2026, a decrease from $717.9 million at the end of 2025, primarily driven by a reduction in marketable securities and the recognition of deferred revenue. The company maintains a cash runway expected to fund operations into the second half of 2028, focusing on clinical advancements for candidates like ARV-393 and ARV-027.
Arvinas reported third quarter 2026 financial results and provided a corporate update on its protein degrader pipeline, including the initiation of a Phase 1/2 trial for its HPK1 degrader ARV-6723. The company ended the quarter with $1.1 billion in cash and equivalents, which it expects will fund operations into 2028. Key upcoming milestones include Phase 1 data readouts for ARV-393, ARV-027, and ARV-6723 through 2027.
“We executed strongly during the quarter and are entering an important period of clinical milestones that we believe will demonstrate the promise of our clinical-stage protein degraders. We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients. The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape, and we are grateful to the patients, investigators, and employees whose commitment makes this progress possible.”
Randy Teel, Ph.D., President and Chief Executive Officer of Arvinas